Diligence memo · auto-generated · as of July 2, 2026

Juvena Therapeutics, Inc.

Juvena Therapeutics, Inc. looks fair against its niche peers and is active on financing cadence.

SourceRaising on rhythm with a 7.1× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

Juvena Therapeutics, Inc. operates in Pharma, based in REDWOOD CITY.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Juvena Therapeutics, Inc. has raised $35M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $30M on 2025-06-27.

Most recent recorded round closed around 2025-06-27.

Valuation (modeled)modeled

Provath models Juvena Therapeutics, Inc. at approximately $144M (range $64M–$214M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.49× the median modeled value of Series B Pharma companies in 2025–2027 (8 peers) — value vs value, same stage and era. Within the normal band (149% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 89 months.

Last raise 12 mo ago; this sector typically re-raises about every 16 months.

Raising on or ahead of the sector's normal rhythm.

The last round stepped up 7.1× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 83% of Pharma peers (310 compared).

Modeled value ranks above 73% of those peers.

Closest niche peers: Alessa Therapeutics, Inc., Amani Therapeutics, Inc., Shenandoah Therapeutics Inc., Atlas Oncology Holdings Inc., TwoStep Therapeutics, Inc..

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.